8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Feb 19, 2026·SEC
Travere Therapeutics, Inc.(TVTX)Earnings, Financials & Key Ratios
TVTX•NASDAQ
$44.77
$4.16B mkt cap·Price updated May 6, 2026
AboutTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Show more
- Revenue$491M+110.5%
- EBITDA-$2M+99.3%
- Net Income-$26M+92.1%
- EPS (Diluted)-0.56+86.3%
- Gross Margin97.89%+1.3%
- EBITDA Margin-0.42%+99.6%
- Operating Margin-12.8%+90.8%
- Net Margin-5.21%+96.2%
- ROE-29.38%+88.1%
- ROIC-12.52%+75.5%
- Debt/Equity2.86-57.9%
- Interest Coverage-3.58+87.0%
TVTX Key Insights
Travere Therapeutics, Inc. (TVTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 31.5%
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓Strong 5Y sales CAGR of 19.9%
✗Weaknesses
- ✗High debt to equity ratio of 2.9x
- ✗Shares diluted 13.1% in last year
- ✗Expensive at 34.8x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TVTX Price & Volume
Travere Therapeutics, Inc. (TVTX) stock price & volume — 10-year historical chart
Loading chart...
TVTX Growth Metrics
Travere Therapeutics, Inc. (TVTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.25%
5 Years19.87%
3 Years64.89%
TTM96.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.14%
Return on Capital
10 Years-32.91%
5 Years-47.14%
3 Years-49.16%
Last Year-14.98%
TVTX Recent Earnings
Travere Therapeutics, Inc. (TVTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 4, 2026EPS
$0.39
Est $0.24
-61.1%
Revenue
$127M
Est $136M
-6.6%
Q1 2026
Feb 19, 2026EPS
$0.03
Est $0.03
+0.0%
Revenue
$130M
Est $145M
-10.3%
Q4 2025
Oct 30, 2025EPS
$0.28
Est $0.31
+190.3%
Revenue
$165M
Est $147M
+12.2%
Q3 2025
Aug 6, 2025EPS
$0.14
Est $0.28
+50.0%
Revenue
$114M
Est $100M
+15.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.39vs $0.24-61.1% | $127Mvs $136M-6.6% |
| Q1 2026 | Feb 19, 2026 | $0.03vs $0.03+0.0% | $130Mvs $145M-10.3% |
| Q4 2025 | Oct 30, 2025 | $0.28vs $0.31+190.3% | $165Mvs $147M+12.2% |
| Q3 2025 | Aug 6, 2025 | $0.14vs $0.28+50.0% | $114Mvs $100M+15.0% |
Based on last 12 quarters of dataView full earnings history →
TVTX Peer Comparison
Travere Therapeutics, Inc. (TVTX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare TVTX vs Peers
Travere Therapeutics, Inc. (TVTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TVTX Income Statement
Travere Therapeutics, Inc. (TVTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 154.94M | 164.25M | 175.34M | 198.32M | 131.84M | 109.46M | 145.24M | 233.18M | 490.73M | 536.2M |
| Revenue Growth % | 15.98% | 6.01% | 6.75% | 13.11% | -33.52% | -16.97% | 32.69% | 60.55% | 110.45% | 96.03% |
| Cost of Goods Sold | 3.6M | 5.53M | 5.23M | 6.13M | 3.82M | 4.42M | 11.45M | 7.74M | 10.34M | 5.66M |
| COGS % of Revenue | 2.33% | 3.37% | 2.99% | 3.09% | 2.9% | 4.04% | 7.88% | 3.32% | 2.11% | - |
| Gross Profit | 151.33M▲ 0% | 158.72M▲ 4.9% | 170.1M▲ 7.2% | 192.19M▲ 13.0% | 128.02M▼ 33.4% | 105.04M▼ 17.9% | 133.79M▲ 27.4% | 225.43M▲ 68.5% | 480.39M▲ 113.1% | 403.34M▲ 0% |
| Gross Margin % | 97.67% | 96.63% | 97.01% | 96.91% | 97.1% | 95.96% | 92.12% | 96.68% | 97.89% | 75.22% |
| Gross Profit Growth % | 17.28% | 4.88% | 7.17% | 12.99% | -33.39% | -17.95% | 27.37% | 68.5% | 113.1% | - |
| Operating Expenses | 182.13M | 227.41M | 269.91M | 368.36M | 327.44M | 424.85M | 521.93M | 549.26M | 543.21M | 587.6M |
| OpEx % of Revenue | 117.55% | 138.46% | 153.94% | 185.74% | 248.37% | 388.14% | 359.36% | 235.56% | 110.7% | - |
| Selling, General & Admin | 103.96M | 103.65M | 128.95M | 135.8M | 126.28M | 197.52M | 265.54M | 264.12M | 337.2M | 344.62M |
| SG&A % of Revenue | 67.1% | 63.11% | 73.54% | 68.47% | 95.79% | 180.45% | 182.83% | 113.27% | 68.71% | - |
| Research & Development | 78.17M | 123.76M | 140.96M | 131.77M | 201.16M | 227.33M | 244.99M | 282.7M | 206.01M | 216.22M |
| R&D % of Revenue | 50.45% | 75.35% | 80.4% | 66.44% | 152.58% | 207.69% | 168.68% | 121.24% | 41.98% | - |
| Other Operating Expenses | 1.11M | -474K | -314K | 100.79M | 0 | 0 | 11.39M | 2.44M | 0 | 1000K |
| Operating Income | -53.79M▲ 0% | -80.04M▼ 48.8% | -99.81M▼ 24.7% | -176.16M▼ 76.5% | -199.43M▼ 13.2% | -319.81M▼ 60.4% | -388.14M▼ 21.4% | -323.83M▲ 16.6% | -62.82M▲ 80.6% | -56.75M▲ 0% |
| Operating Margin % | -34.72% | -48.73% | -56.92% | -88.83% | -151.27% | -292.17% | -267.24% | -138.88% | -12.8% | -10.58% |
| Operating Income Growth % | 7.6% | -48.8% | -24.7% | -76.5% | -13.2% | -60.37% | -21.36% | 16.57% | 80.6% | - |
| EBITDA | -35.99M | -61.37M | -79.4M | -151.58M | -186.68M | -299.09M | -349.61M | -280.27M | -2.08M | -8.81M |
| EBITDA Margin % | -23.23% | -37.37% | -45.29% | -76.43% | -141.6% | -273.25% | -240.71% | -120.2% | -0.42% | -1.64% |
| EBITDA Growth % | 14.48% | -70.54% | -29.38% | -90.9% | -23.15% | -60.22% | -16.89% | 19.83% | 99.26% | 95.11% |
| D&A (Non-Cash Add-back) | 17.8M | 18.67M | 20.41M | 24.58M | 12.75M | 20.72M | 38.53M | 43.55M | 60.74M | 47.94M |
| EBIT | -53.94M | -92.06M | -127.62M | -169.74M | -197.2M | -320.14M | -364.78M | -309.33M | -38.52M | -193K |
| Net Interest Income | -1.19M | -4.31M | -8.77M | -14.05M | -17.69M | -4.74M | 10.43M | 6.63M | 1.97M | 1.03M |
| Interest Income | 3.23M | 5.5M | 10.05M | 5M | 1.99M | 6.28M | 21.77M | 17.82M | 12.72M | 11.51M |
| Interest Expense | 4.42M | 9.81M | 18.83M | 19.05M | 19.68M | 11.01M | 11.33M | 11.18M | 10.75M | 5.59M |
| Other Income/Expense | -30.19M | -21.83M | -46.64M | -12.63M | -17.46M | -11.34M | 12.03M | 3.32M | 13.55M | 11.94M |
| Pretax Income | -58.36M▲ 0% | -101.87M▼ 74.5% | -146.45M▼ 43.8% | -188.79M▼ 28.9% | -216.88M▼ 14.9% | -331.15M▼ 52.7% | -376.11M▼ 13.6% | -320.51M▲ 14.8% | -49.27M▲ 84.6% | -44.81M▲ 0% |
| Pretax Margin % | -37.67% | -62.02% | -83.52% | -95.19% | -164.51% | -302.54% | -258.96% | -137.45% | -10.04% | -8.36% |
| Income Tax | 1.37M | 811K | -21K | -19.36M | 409K | 313K | 223K | 120K | 988K | 1.07M |
| Effective Tax Rate % | -2.34% | -0.8% | 0.01% | 10.25% | -0.19% | -0.09% | -0.06% | -0.04% | -2.01% | -2.39% |
| Net Income | -59.73M▲ 0% | -102.68M▼ 71.9% | -146.43M▼ 42.6% | -169.43M▼ 15.7% | -180.09M▼ 6.3% | -278.48M▼ 54.6% | -111.4M▲ 60.0% | -321.55M▼ 188.6% | -25.55M▲ 92.1% | -21.42M▲ 0% |
| Net Margin % | -38.55% | -62.51% | -83.51% | -85.43% | -136.6% | -254.41% | -76.7% | -137.9% | -5.21% | -4% |
| Net Income Growth % | -24.69% | -71.9% | -42.61% | -15.71% | -6.29% | -54.63% | 60% | -188.64% | 92.06% | 90.55% |
| Net Income (Continuing) | -59.73M | -102.68M | -146.43M | -169.43M | -217.29M | -331.47M | -376.33M | -320.63M | -50.26M | -46.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 37.2M | 52.99M | 264.93M | -915K | 24.71M | 1000K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.54▲ 0% | -2.54▼ 64.9% | -3.46▼ 36.2% | -3.56▼ 2.9% | -3.01▲ 15.4% | -4.37▼ 45.2% | -1.50▲ 65.7% | -4.08▼ 172.0% | -0.56▲ 86.3% | -0.23▲ 0% |
| EPS Growth % | -23.2% | -64.94% | -36.22% | -2.89% | 15.45% | -45.18% | 65.68% | -172% | 86.27% | 81.14% |
| EPS (Basic) | -1.54 | -2.54 | -3.46 | -3.56 | -3.01 | -4.37 | -1.50 | -4.08 | -0.56 | - |
| Diluted Shares Outstanding | 38.77M | 40.43M | 42.34M | 47.54M | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M | 91.87M |
| Basic Shares Outstanding | 38.77M | 40.42M | 42.34M | 47.54M | 59.83M | 63.76M | 74.27M | 78.89M | 89.21M | 91.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TVTX Balance Sheet
Travere Therapeutics, Inc. (TVTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 325.81M | 495.68M | 429.06M | 410.41M | 582.83M | 486.44M | 616.77M | 416.7M | 437.56M | 392.68M |
| Cash & Short-Term Investments | 300.63M | 471.54M | 398.52M | 361.59M | 552.88M | 450.25M | 566.85M | 370.7M | 322.8M | 264.68M |
| Cash Only | 99.39M | 102.87M | 62.44M | 84.77M | 165.75M | 61.69M | 58.18M | 58.53M | 93.03M | 78.36M |
| Short-Term Investments | 201.24M | 368.67M | 336.09M | 276.82M | 387.13M | 388.56M | 508.68M | 312.17M | 229.76M | 186.31M |
| Accounts Receivable | 13.87M | 14.49M | 18.05M | 33.07M | 15.91M | 16.65M | 21.18M | 27.12M | 80.13M | 87.3M |
| Days Sales Outstanding | 32.68 | 32.2 | 37.57 | 60.86 | 44.06 | 55.51 | 53.23 | 42.45 | 59.6 | 49.43 |
| Inventory | 5.35M | 5.62M | 6.08M | 7.61M | 7.31M | 4.52M | 9.41M | 6.2M | 5.88M | 6.36M |
| Days Inventory Outstanding | 541.78 | 371.08 | 424.14 | 453.3 | 699.12 | 373.51 | 299.97 | 292.23 | 207.41 | 352.63 |
| Other Current Assets | 5.95M | 2.31M | 5.01M | 0 | 247K | 15.02M | 19.34M | 12.69M | 28.76M | 34.35M |
| Total Non-Current Assets | 194.54M | 213.48M | 175.74M | 197.03M | 193.77M | 186.19M | 172.14M | 177.42M | 167.63M | 162.51M |
| Property, Plant & Equipment | 3.23M | 3.15M | 9.89M | 9.42M | 34.3M | 30.05M | 25.54M | 19.63M | 14.6M | 13.29M |
| Fixed Asset Turnover | 47.97x | 52.21x | 17.74x | 21.06x | 3.84x | 3.64x | 5.69x | 11.88x | 33.62x | 35.41x |
| Goodwill | 936K | 936K | 936K | 936K | 900K | 800K | 753K | 753K | 0 | 0 |
| Intangible Assets | 184.82M | 186.69M | 157.2M | 153.19M | 147.5M | 96.32M | 103.69M | 103.22M | 113.87M | 110.04M |
| Long-Term Investments | -16.81M | 15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 5.56M | -25M | 7.71M | 33.49M | 11.07M | 59.03M | 42.16M | 53.82M | 39.16M | 173.82M |
| Total Assets | 520.35M▲ 0% | 709.16M▲ 36.3% | 604.8M▼ 14.7% | 607.44M▲ 0.4% | 776.63M▲ 27.9% | 672.59M▼ 13.4% | 788.91M▲ 17.3% | 594.13M▼ 24.7% | 605.19M▲ 1.9% | 555.19M▲ 0% |
| Asset Turnover | 0.30x | 0.23x | 0.29x | 0.33x | 0.17x | 0.16x | 0.18x | 0.39x | 0.81x | 0.95x |
| Asset Growth % | -0.94% | 36.29% | -14.72% | 0.44% | 27.85% | -13.4% | 17.3% | -24.69% | 1.86% | 10.56% |
| Total Current Liabilities | 85.67M | 104.62M | 95.45M | 92.66M | 124.09M | 142.16M | 177.91M | 200.75M | 159.9M | 125.44M |
| Accounts Payable | 18.94M | 6.95M | 26.61M | 12.13M | 15.14M | 17.29M | 41.67M | 23.53M | 24.8M | 12.91M |
| Days Payables Outstanding | 1.92K | 459.24 | 1.86K | 722.91 | 1.45K | 1.43K | 1.33K | 1.11K | 875.52 | 1.21K |
| Short-Term Debt | 0 | 22.46M | 2.61M | 0 | 0 | 0 | 0 | 68.68M | 5.88M | 6.02M |
| Deferred Revenue (Current) | 0 | 49.7M | 0 | 0 | 16.27M | 11.98M | 7.1M | 2.81M | 0 | 0 |
| Other Current Liabilities | 58.98M | 64.76M | 52.18M | 62.26M | 39.59M | 47.99M | 94.32M | 100.32M | 129.23M | 106.51M |
| Current Ratio | 3.80x | 4.74x | 4.50x | 4.43x | 4.70x | 3.42x | 3.47x | 2.08x | 2.74x | 2.74x |
| Quick Ratio | 3.74x | 4.68x | 4.43x | 4.35x | 4.64x | 3.39x | 3.41x | 2.04x | 2.70x | 2.70x |
| Cash Conversion Cycle | -1.34K | -55.96 | -1.39K | -208.75 | -704.58 | -998.78 | -975.31 | -774.56 | -608.51 | -808.44 |
| Total Non-Current Liabilities | 141.54M | 286.29M | 288.15M | 303.57M | 350.43M | 487.57M | 410.19M | 334.3M | 330.46M | 331.02M |
| Long-Term Debt | 45.08M | 195.09M | 204.86M | 215.34M | 226.58M | 375.55M | 377.26M | 310.31M | 322.86M | 321.64M |
| Capital Lease Obligations | 0 | 0 | 7.39M | 28.34M | 31.5M | 27.51M | 22.61M | 17.19M | 0 | 25.26M |
| Deferred Tax Liabilities | 16.81M | 32.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 96.47M | 91.19M | 75.9M | 59.89M | 71.98M | 73.58M | 8.48M | 6.8M | 7.6M | 19.66M |
| Total Liabilities | 227.21M | 390.91M | 383.6M | 396.23M | 474.52M | 629.73M | 588.1M | 535.05M | 490.36M | 456.46M |
| Total Debt | 45.08M | 217.55M | 214.87M | 244.03M | 261.99M | 407.49M | 404.78M | 401.58M | 328.73M | 327.66M |
| Net Debt | -54.32M | 114.67M | 152.43M | 159.26M | 96.23M | 345.8M | 346.61M | 343.05M | 235.7M | 249.3M |
| Debt / Equity | 0.15x | 0.68x | 0.97x | 1.16x | 0.87x | 9.51x | 2.02x | 6.80x | 2.86x | 2.86x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -37.20x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -28.30x |
| Interest Coverage | -12.20x | -9.38x | -6.78x | -8.91x | -10.02x | -29.07x | -32.18x | -27.66x | -3.58x | -0.03x |
| Total Equity | 293.13M▲ 0% | 318.25M▲ 8.6% | 221.2M▼ 30.5% | 211.21M▼ 4.5% | 302.11M▲ 43.0% | 42.85M▼ 85.8% | 200.81M▲ 368.6% | 59.08M▼ 70.6% | 114.83M▲ 94.4% | 98.73M▲ 0% |
| Equity Growth % | -4.75% | 8.57% | -30.5% | -4.51% | 43.04% | -85.82% | 368.62% | -70.58% | 94.37% | 752.91% |
| Book Value per Share | 7.56 | 7.87 | 5.22 | 4.44 | 5.05 | 0.67 | 2.70 | 0.75 | 1.29 | 1.07 |
| Total Shareholders' Equity | 293.13M | 318.25M | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M | 59.08M | 114.83M | 98.73M |
| Common Stock | 4K | 4K | 4K | 5K | 6K | 6K | 7K | 9K | 9K | 9K |
| Retained Earnings | -177.66M | -270.02M | -416.44M | -585.88M | -765.97M | -1.01B | -1.13B | -1.45B | -1.47B | -1.51B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.01M | -1.53M | 726K | -902K | -562K | -2.91M | -1.46M | -80K | -1.19M | -1.06M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TVTX Cash Flow Statement
Travere Therapeutics, Inc. (TVTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 7.4M | -24.96M | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M | -237.47M | 37.78M | 37.78M |
| Operating CF Margin % | 4.78% | -15.2% | -33.2% | -21.55% | -11.22% | -170.19% | -192.8% | -101.84% | 7.7% | - |
| Operating CF Growth % | 563.85% | -437.13% | -133.25% | 26.58% | 65.39% | -1159.4% | -50.31% | 15.19% | 115.91% | 520.27% |
| Net Income | -59.73M | -102.68M | -146.43M | -169.43M | -217.29M | -331.47M | -376.33M | -320.63M | -25.55M | -21.42M |
| Depreciation & Amortization | 17.8M | 18.67M | 20.41M | 24.58M | 12.75M | 20.72M | 38.53M | 43.55M | 60.74M | 73.15M |
| Stock-Based Compensation | 26.87M | 19.77M | 21.11M | 23.61M | 29.57M | 38.14M | 44.25M | 36.91M | 44.87M | 38.06M |
| Deferred Taxes | -6.42M | 20.34M | 0 | 1.99M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 25.07M | 7.86M | 44.08M | 102.54M | 79.41M | 85.44M | 39.01M | 65.71M | -28.28M | 9.46M |
| Working Capital Changes | 3.81M | 11.07M | 2.62M | -26.04M | 80.78M | 875K | -25.48M | -63.02M | -14M | -35.42M |
| Change in Receivables | 4.95M | 152K | -4.63M | 2.3M | 17.95M | -1.43M | -11.3M | -6.04M | -27.82M | -27.84M |
| Change in Inventory | -1.71M | -2.77M | -1.96M | -5.07M | 117K | -1.21M | -39.42M | -3.77M | 5.02M | 610K |
| Change in Payables | 2.66M | -2.71M | 9.26M | -6.04M | 2.47M | 2.06M | 24.76M | -17.56M | -85K | -3.59M |
| Cash from Investing | 45.6M | -203.29M | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M | 99.33M | 27.89M | 8.15M |
| Capital Expenditures | -14.01M | -19.7M | -195K | -119.84M | -5.1M | -191K | -668K | 0 | 0 | -56.47M |
| CapEx % of Revenue | 9.04% | 11.99% | 0.11% | 60.43% | 3.87% | 0.17% | 0.46% | 43.41% | - | - |
| Acquisitions | -13.12M | -15M | 0 | 113.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 60.62M | -202.56M | -15.37M | -113.08M | -19.05M | -28.97M | 165.81M | -101.25M | -58.56M | -12.41M |
| Cash from Financing | 5.45M | 231.86M | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M | 139.42M | -33.47M | -32.98M |
| Debt Issued (Net) | 0 | 235.8M | 0 | 0 | 0 | 104.93M | 0 | 0 | -68.9M | -68.9M |
| Equity Issued (Net) | 0 | 0 | 0 | 131.52M | 224.93M | 19.55M | 191.2M | 134.74M | 37.54M | 38.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 5.45M | -3.93M | -2.08M | -3.81M | 6.75M | -6.9M | 27.55M | 4.68M | -2.1M | -2.1M |
| Net Change in Cash | 58.39M▲ 0% | 3.48M▼ 94.0% | -40.44M▼ 1262.3% | 22.34M▲ 155.2% | 80.98M▲ 262.6% | -104.06M▼ 228.5% | -3.51M▲ 96.6% | 359K▲ 110.2% | 34.5M▲ 9510.0% | 16.46M▲ 0% |
| Free Cash Flow | -6.61M▲ 0% | -44.66M▼ 576.0% | -73.78M▼ 65.2% | -162.59M▼ 120.4% | -38.94M▲ 76.0% | -214.66M▼ 451.2% | -321.61M▼ 49.8% | -338.69M▼ 5.3% | 37.78M▲ 111.2% | 17.43M▲ 0% |
| FCF Margin % | -4.26% | -27.19% | -42.08% | -81.98% | -29.54% | -196.11% | -221.44% | -145.25% | 7.7% | 3.25% |
| FCF Growth % | 51.14% | -576.04% | -65.21% | -120.37% | 76.05% | -451.21% | -49.83% | -5.31% | 111.16% | 108.62% |
| FCF per Share | -0.17 | -1.10 | -1.74 | -3.42 | -0.65 | -3.37 | -4.33 | -4.29 | 0.42 | 0.42 |
| FCF Conversion (FCF/Net Income) | -0.12x | 0.24x | 0.40x | 0.25x | 0.08x | 0.67x | 2.51x | 0.74x | -1.48x | -0.81x |
| Interest Paid | 2.07M | 1.88M | 7.67M | 0 | 7.33M | 10.16M | 8.84M | 0 | 0 | 0 |
| Taxes Paid | 7.17M | 218K | 656K | 0 | 16.42M | 0 | 0 | 0 | 0 | 0 |
TVTX Key Ratios
Travere Therapeutics, Inc. (TVTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -19.88% | -33.59% | -54.29% | -78.37% | -70.17% | -161.46% | -91.44% | -247.45% | -29.38% | -26.79% |
| Return on Invested Capital (ROIC) | -14.67% | -17.87% | -18.56% | -35.51% | -38.91% | -60.96% | -62.2% | -51.16% | -12.52% | -12.52% |
| Gross Margin | 97.67% | 96.63% | 97.01% | 96.91% | 97.1% | 95.96% | 92.12% | 96.68% | 97.89% | 75.22% |
| Net Margin | -38.55% | -62.51% | -83.51% | -85.43% | -136.6% | -254.41% | -76.7% | -137.9% | -5.21% | -4% |
| Debt / Equity | 0.15x | 0.68x | 0.97x | 1.16x | 0.87x | 9.51x | 2.02x | 6.80x | 2.86x | 2.86x |
| Interest Coverage | -12.20x | -9.38x | -6.78x | -8.91x | -10.02x | -29.07x | -32.18x | -27.66x | -3.58x | -0.03x |
| FCF Conversion | -0.12x | 0.24x | 0.40x | 0.25x | 0.08x | 0.67x | 2.51x | 0.74x | -1.48x | -0.81x |
| Revenue Growth | 15.98% | 6.01% | 6.75% | 13.11% | -33.52% | -16.97% | 32.69% | 60.55% | 110.45% | 96.03% |
TVTX SEC Filings & Documents
Travere Therapeutics, Inc. (TVTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TVTX Frequently Asked Questions
Travere Therapeutics, Inc. (TVTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Travere Therapeutics, Inc. (TVTX) reported $536.2M in revenue for fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) grew revenue by 110.5% over the past year. This is strong growth.
Travere Therapeutics, Inc. (TVTX) reported a net loss of $21.4M for fiscal year 2025.
Dividend & Returns
Travere Therapeutics, Inc. (TVTX) has a return on equity (ROE) of -29.4%. Negative ROE indicates the company is unprofitable.
Travere Therapeutics, Inc. (TVTX) generated $17.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More TVTX
Travere Therapeutics, Inc. (TVTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates